All In Biotech

NDA 210595 · Azurity

Duaklir Pressair

Aclidinium Bromide, Formoterol Fumarate · Inhalation

Discontinued

Last checked: Nov 19, 2026Latest source record: Mar 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 29, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

21 Phase 3, 0 recruiting

FAERS reports

29

6 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2022.

DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.4 )] . DUAKLIR PRESSAIR is a combination of aclidinium bromide an anticholinergic, and formoterol fumarate, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.4 )

Mechanism: DUAKLIR PRESSAIR DUAKLIR PRESSAIR contains two bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Further information regarding these two substances is provided below. The mechanism of action described below for the individual components apply to DUAKLIR PRESSAIR. These drugs represent two different classes of medications (a long-acting antimuscarinic agent and a selective long-acting beta 2 -adrenergic receptor agonist) that have different effects on clinical and physiological indices of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DUAKLIR PRESSAIR · ACLIDINIUM BROMIDE 0.4MG/INH; FORMOTEROL FUMARATE 0.012MG/INH · POWDER, METERED, INHALATION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Aclidinium" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue12
  • device issue4
  • dyspnoea4
  • device defective2
  • parosmia2
  • taste disorder2
  • adverse event1
  • asphyxia1
  • atrioventricular block complete1
  • cardiac failure congestive1
  • chronic obstructive pulmonary disease1
  • confusional state1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
20207
20213
20224
20232
20243
20256
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Duaklir Pressair (Aclidinium Brom/Formoterol Fum)

2024 spending

$60K

Beneficiaries

64

155 claims

Per beneficiary

$930

$347.33 per unit

View as table
YearSpending
2020$429,432
2021$346,689
2022$70,451
2023$49,015
2024$59,508

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 79 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.